Dr. Jagasia is a laboratory head of the Human Neural Stem Cell Lab and project leader for small molecule drug discovery programs for: 1) neuroregenerative therapy for Alzheimer’s; 2) disease modifying therapy for Autism Spectrum Disorders; and 3) disease modifying therapy for Parkinson’s. The focus of his laboratory has been to develop protocols to differentiate physiologically relevant neurons, development of several phenotypic screens (High Throughput and High Content Screening, HTS/HCS) and to establish novel technologies at Roche (eg. genome editing, ribosomal profiling, human pluripotent stem cells etc).
Prior to joining Roche in his current role, Dr. Jagasia did a postdoc at the Helmholtz Zentrum in München focused on models of CNS neuroregeneration (maturation of newborn granule neurons in the adult dentate gyrus) and neurodegeneration of the nervous system (in vivo model for astrocyte induced mitochondrial dysfunction). During his PhD at the Max-Planck Institute fur Neurobiologie in Martinsried, Dr. Jagasia demonstrated the importance of mitochondrial proteins in developmental programmed cell death in vivo.
Dr. Jagasia holds a PhD in from the Adolf-Butenandt-Institut für Physiologische Chemie at the Ludwig-Maximilians Universität in München, and a Master ’s and Bachelor’s of Science from the University of Toronto Department of Physiology.
For detail and recent publications: https://www.ncbi.nlm.nih.gov/pubmed/?term=Jagasia+R